E. coli, E. faecalis, K. pneumonaie, or P. mirabalis. Pathogens, resistance, treatment success, and medication side effects were specific to postmenopausal women. RESULTS: In terms of our results, we assumed 73.4% of UTIs were caused by E.coli strains with a 24.4% resistance to TMP/SMX. With our assumptions, eABX TMP/SMX was the least costly approach ($89.64/patient, Table 1), followed by waiting for Ucx($97.04/patient). For any given antibiotic, eABX was always less costly than using U/A first. This is due to cost of U/A ($38.23), high rate of UTI (90%) in PMP women with dysuria, and resultant high rate of ABX with or without U/A. Options with fosfomycin were the most expensive due to highest drug costs($98/dose), and tornado analyses showed fosfomycin cost was the most impactful variable for model outcomes. Sensitivity analyses showed eABX fosfomycin became the least costly option if drug costs were $25.80. This outcome was largely predicated on low resistance to fosfomycin. Conversely, ciprofloxacin was never the least costly option due to higher resistance and side effect cost, even if the drug cost was $0. CONCLUSION: In conclusion, the least costly strategy was eABX TMP/ SMX, followed by waiting on Ucx. Local resistance patterns will impact cost minimization strategies. Fosfomycin eABX would be least costly with reduced drug costs. In a population with high posttest probability of positive Ucx, U/A adds unnecessary cost. Antibiotic stewardship should continue efforts to decrease fluoroquinolone use due to high resistance, side effects, and increased cost.
Obstetrics and Gynecology, University of New Mexico, Albuquerque, NM OBJECTIVES: Adverse Childhood Experiences (ACEs), traumatic events occurring during childhood, are not well recognized in the gynecologic community but are associated with life-long deleterious effects. The objective of this study was to bridge the information gap regarding ACEs in the chronic pelvic pain (CPP) population by (1) describing ACE prevalence in women with chronic pelvic pain (CPP), and (2) comparing ACE prevalence in women with CPP to unaffected controls. MATERIALS AND METHODS: This is a cross-sectional case-control study designed to examine the relationship of ACEs with CPP. Following IRB approval and written consent, patients diagnosed with CPP (n¼60) were age-matched to controls (n¼60). All participants completed validated measures to evaluate for presence any of the 11 ACEs (BRFSS ACE Module), as identified by the Center for Disease Control, during their initial clinic visit. The BRFSS ACE Module also sub-categorizes ACEs into abuse and household dysfunction. Significance was set at p<.05. RESULTS: The mean age of CPP women was 39.6 (AE11.5) years, 52% were Hispanic (groups did not differ p>.05). We found that almost half (45%) of the CPP subjects had !5 ACEs, compared to 13% of controls (OR¼ 5.32; 95% CI 2.16-13.1); and found a strong logistic-regression relationship between number of ACEs and CPP (p<0.001) ( Table 1 ). All categories of abuse were more prevalent in CPP patients compared to controls: physical (43% vs. 15%, OR¼4.3; 95% CI 1.8-10.4; p¼.001), verbal/emotional (62% vs 33%, OR¼3.2; 95% CI 1.5-6.8; p¼.003), and sexual (55% vs. 23%, OR¼4.0; 95% CI 1.8-8.8; p<.001). Two categories of household dysfunction, substance abuse (45% vs. 25%, OR¼2.5; 95% CI 1.1-5.3; p¼.035) and witnessed domestic violence (35% vs 8%; OR¼5.9; 95% CI 2.1-17.1; p<.001) were more prevalent in the CPP group (Table 2) . CONCLUSION: CPP patients are likely to have high numbers of ACEs. This suggests that CPP symptomatology may, in part, be a manifestation of childhood exposures. In turn, it may require reconsideration of current clinical treatment, and a multi-disciplinary approach tailoring non-surgical and surgical management.
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OBJECTIVES:
To compare histological and biomechanical properties of a permanent sling mesh to 2 differently woven delayed absorbable mesh in a rabbit model. MATERIALS AND METHODS: A permanent polypropylene (PP) mesh, delayed absorbable poly-4-hydroxybutyrate (P4HB) crochet-weave (CW) mesh, and delayed absorbable P4HB net-weave (NW) mesh were used. 3 rabbits were implanted with the 3 different mesh types abdominally, measuring 8.0x1.1 cm, and anterior and posterior vagina with a different mesh type, measuring 1.5x1.1 cm. At 3 months, implants were harvested and underwent histological and biomechanical testing. Two blinded pathologists graded histological samples on a scale of 0 to 3 for inflammation, collagen deposition, and elastic composition. Collagen I/III ratio was also calculated. An Instron machine (Model #5566) was used to perform load to failure biomechanical testing to assess ultimate tensile strength (UTS) and stiffness. Descriptive statistics were used for all variables. RESULTS: All rabbits tolerated implantation well. No mesh exposures were noted. Vaginally, CW decreased most in length and width by 32.8% and 37%, respectively. NW decreased in length by 27.3% and width by 16.6%. PP decreased in length by 11.1% and width by 2.6%. Results were similar abdominally; CW had the most tissue contraction with change in length and width by 23.9% and 21.1%, respectively. NW decreased in length by 26.3% and width by 4.4%. PP decreased in length by 15.1% with no change in width. Histological evaluation of vaginal samples showed no acute inflammation (Score¼0) and scant chronic inflammation (Score¼1). CW had the least inflammatory cells (Score¼1), while NW and PP showed slightly more inflammation (Score¼1.5). Abdominal samples revealed similar results, with all mesh-tissue specimens noted to have chronic inflammation (Score¼1.5). No neovascularization was seen in vaginal and abdominal samples. Collagen deposition was noted in the vaginal NW and PP samples (Score¼1.5), CW had scant collagen deposition (Score¼1). Abdominally, moderate collagen deposition was noted in all meshtissue samples (Score¼2). Elastin was not seen in CW and NW abdominally and vaginally (Score¼0), but scant was noted in PP vaginally (Score¼1). Type I collagen was the predominant collagen vaginally and abdominally. Biomechanical testing was successful for both vaginal and abdominal samples. Vaginally, the UTS of PP was 0.2 Mpa, while NW was 0.1 Mpa and CW was 0.4 Mpa. PP had the most stiffness at 3.9 N/mm, while NW and CW was 2.8 N/mm and 2.2 N/mm, respectively. CONCLUSION: Overall, the 3 meshes exhibited similar histologic responses, but CW exhibited the most tissue contraction with the least inflammatory reaction and collagen deposition. CW had the highest UTS while PP had the highest stiffness. Future time points can provide more information regarding the tissue response to the PP and different P4HB weaves.
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